Udex

Quick links to important sections

Udex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Udex

Property Description
Active ingredient Ursodeoxycholic Acid (UDCA)
Form Oral tablet or capsule
Pharmacological class Bile Acid Preparation, Choleretic Agent
General purpose Bile modification and cellular protection
Origin Naturally-occurring secondary bile acid (Synthetically manufactured)

What Type of Medicine is Udex (Ursodeoxycholic Acid)?

Udex is the commercial name for a medication whose active substance is Ursodeoxycholic Acid (UDCA). This compound is classified by major pharmacopeias as a Bile Acid Preparation and a Choleretic Agent. This designation indicates the drug’s function is to chemically modify the composition of bile and influence its flow within the liver and biliary tract. The product is manufactured for oral administration, typically provided as a single active ingredient product in solid tablet or capsule forms. The use of UDCA is clinically recognized for its role in altering bile chemistry.

Composition and Origin: Is Udex a Natural Compound?

The active ingredient, Ursodeoxycholic Acid, is a secondary bile acid that occurs naturally in the human body, though only in small amounts. To ensure the high purity and specific concentration required for reliable therapeutic effect, the UDCA found in Udex is manufactured synthetically. Udex is a single-component pharmaceutical, comprising only the UDCA active compound combined with the necessary solid pharmaceutical excipients (such as binders and fillers) to create a stable, administrable oral product.

What is the General Purpose of This Bile Acid Agent?

The general purpose of Udex is to achieve a cytoprotective (cell-protecting) and therapeutic bile-modifying effect. It functions by becoming the dominant bile acid within the bile acid pool, displacing the more hydrophobic, potentially aggressive bile acids. This cytoprotective action helps stabilize and protect the cell membranes in the liver and bile ducts. This mechanism allows the agent to simultaneously facilitate improved bile flow and reduce the saturation of cholesterol in the bile, generally supporting the overall physiological efficiency of the biliary tract.

What side effects are possible with Udex?

Possible Side Effects and Safety Information

The official safety profile for Udex (Ursodeoxycholic Acid) is classified by regulatory authorities based on the frequency and the organ system affected.

Adverse Reaction Classification

Adverse reactions are formally grouped into system-organ classes, with the most frequently documented effects occurring within Gastrointestinal Disorders. The most common reactions, defined as occurring in up to 1 in 10 patients, include diarrhoea and pasty stools (soft stools).

Other adverse effects, classified as uncommon or by spontaneous reporting, may involve other gastrointestinal symptoms or reactions in the Skin and Subcutaneous Tissue Disorders, such as urticaria (hives) or pruritus (itching).

Serious Adverse Reactions and Hepatobiliary Events

Events affecting Hepatobiliary Disorders are noted in regulatory safety documents. These include the very rare occurrence of calcification of previously non-calcified gallstones. A significant concern is the potential for elevation of liver enzyme values (e.g., ALT, AST, GGT) that may, in serious cases, require the cessation of treatment.

Specific to patients with Primary Biliary Cholangitis (PBC), regulatory labeling notes the possibility of temporary worsening of existing symptoms, such as pruritus, during the initial months of therapy. This necessitates periodic monitoring of liver function parameters during the first three months of treatment and regularly thereafter, as a documented safety measure.

Safety-Related Restrictions

Udex is formally contraindicated by regulatory bodies in the presence of certain conditions, including acute inflammation of the gallbladder or bile ducts, total obstruction of the bile duct, a non-functioning gallbladder, peptic ulcers, and the presence of calcified (radiopaque) gallstones. These restrictions establish the limitations for its safe use as documented in official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Udex (Ursodeoxycholic Acid) as primarily linked to gastrointestinal effects following the ingestion of an excessively large dose.

Documented Overdose Manifestations

The most commonly documented clinical manifestation of overdose is diarrhea, which may become severe and persistent. Other non-specific gastrointestinal disturbances may also occur. The chief serious risk cited is the potential for severe diarrhea to lead to significant dehydration and electrolyte disturbances if not promptly addressed.

Regulatory Mandates for Emergency Action

Action/Condition Requirement as Stated in Official Labeling
Immediate Help Seek immediate medical attention if a large ingestion is suspected.
Symptom Trigger Consult a healthcare provider if severe and persistent diarrhea develops.
Antidote Status No specific antidote is known to be available.
Management Treatment is symptomatic and supportive, focusing on correcting fluid and electrolyte loss.
Monitoring Hospital monitoring may be required in cases of high ingestion or severe, prolonged symptoms.

The official approach for managing an overdose is constrained to supportive measures, as regulatory agencies confirm the lack of a specific pharmacological reversal agent. The severity of the gastrointestinal symptoms—specifically severe diarrhea—serves as the mandatory regulatory trigger for seeking urgent medical assistance.

Therapeutic Uses of Udex

Therapeutic Indications

Udex is a corticosteroid medication primarily indicated for the management of various inflammatory and autoimmune conditions. By modulating the body's immune response, it helps reduce swelling, redness, and pain associated with systemic inflammation.

Primary Uses

  • Endocrine Disorders: Used in the management of primary or secondary adrenocortical insufficiency.
  • Rheumatic Disorders: Employed as adjunctive therapy for short-term administration in acute episodes or exacerbations of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
  • Collagen Diseases: Utilized during exacerbations or as maintenance therapy in selected cases of systemic lupus erythematosus and acute rheumatic carditis.
  • Dermatologic Diseases: Applied in the treatment of severe skin conditions such as pemphigus, erythema multiforme (Stevens-Johnson syndrome), and exfoliative dermatitis.
  • Allergic States: Management of severe or incapacitating allergic conditions that do not respond to conventional treatments, including bronchial asthma, contact dermatitis, and seasonal or perennial allergic rhinitis.
  • Ophthalmic Diseases: Treatment of severe acute and chronic allergic and inflammatory processes involving the eye.
  • Hematologic Disorders: Management of acquired hemolytic anemia and secondary thrombocytopenia.

Benefits and Mechanism of Action

The primary benefit of Udex lies in its potent anti-inflammatory properties. As a glucocorticoid, it enters cells and binds to specific receptors, influencing gene expression to inhibit the production of inflammatory mediators. This action results in several clinical advantages:

  • Reduction of Edema: It helps decrease fluid accumulation in tissues, which is particularly beneficial in inflammatory joint conditions or cerebral edema.
  • Immune Suppression: By reducing the activity of the lymphatic system, Udex helps control overactive immune responses that lead to tissue damage in autoimmune diseases.
  • Symptom Relief: It provides significant relief from the heat, swelling, and tenderness associated with acute inflammatory flares.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Udex?

Official regulatory criteria strictly define eligibility for Udex (Ursodeoxycholic Acid) based on a patient’s specific anatomical status, age, and disease severity. Use is established for adults requiring treatment for Primary Biliary Cholangitis (PBC) and for the dissolution of specific radiolucent, noncalcified cholesterol gallstones. Pediatric use is specifically established for children and adolescents aged 6 to 18 years for hepatobiliary disorders associated with cystic fibrosis, but use for other indications is not.

The medicine is contraindicated in any patient with a biliary tract occlusion (blockage), acute inflammation of the gallbladder, or impaired gallbladder contractility. Absolute non-eligibility also applies to individuals with radio-opaque calcified gallstones, frequent episodes of biliary colic, or severe hepatic disease, such as decompensated cirrhosis.

For women of childbearing potential being treated for gallstone dissolution, use is restricted and contingent upon the use of effective non-hormonal contraception. During pregnancy and lactation, Udex is generally not recommended, and if treatment is necessary while breastfeeding, official labels advise discontinuation of nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Udex (Ursodeoxycholic Acid) details several interaction patterns, primarily related to drug absorption and opposing pharmacological effects.

Interaction Classifications

Classification Official Regulatory Documentation
Adsorption Interference Bile Acid Sequestering Agents (e.g., Cholestyramine) and Aluminum-based Antacids
Pharmacodynamic Conflict Estrogens, Oral Contraceptives, and Fibrates (e.g., Clofibrate)
Metabolic Alteration Specific Cytochrome P450 3A (CYP3A) substrates (e.g., Cyclosporine, Nitrendipine, Dapsone)

Interaction Requirements and Restrictions

Certain substances must be separated in time because they reduce Udex absorption. Bile Acid Sequestering Agents and Aluminum-based Antacids bind to Udex in the intestinal tract, significantly lowering its systemic exposure. Administration of Udex must be separated from these adsorbing agents to ensure proper absorption.

Estrogens, Oral Contraceptives, and Fibrates should not be co-administered because they increase cholesterol secretion into the bile. This official restriction is based on a pharmacodynamic conflict, as the co-administered agents counteract the intended bile-modifying effect of Udex, diminishing its therapeutic efficacy.

Udex co-administration can also alter the plasma concentration of other medicines, specifically those metabolized via the CYP3A pathway, such as Cyclosporine, Nitrendipine, and Dapsone.

Mechanism of Action

Udex, also known as ursodeoxycholic acid (UDCA), is a hydrophilic bile acid that becomes a major constituent of the circulating bile acid pool following administration. This modifies the overall hydrophobicity index of the endogenous bile acid mixture by competitively displacing more hydrophobic bile acids, which exhibit detergent-like hepatotoxic properties.

The molecule exerts its effects through several intracellular and systemic pathways. In the liver, it acts as a cytoprotectant for hepatocytes and cholangiocytes. This action is mediated by the stimulation of anti-apoptotic pathways and the inhibition of mitochondrial dysfunction and subsequent generation of reactive oxygen species (ROS) induced by toxic bile acids. Udex can also stimulate vesicular exocytosis and upregulate the expression of membrane transport proteins, such as the chloride-bicarbonate anion exchanger (AE2), thereby promoting bile acid and fluid secretion (choleretic action).

At the system level, this modulation of the bile acid profile and the increased flow results in the systemic physiological consequence of altered hepatic function and improved biliary secretion.

Dosage and Administration Information

How Udex is Used: Official Administration Guidelines

Ursodeoxycholic Acid (Udex) is administered orally, with dosage determined by the specific condition being managed and the patient's body weight. The daily dose for Primary Biliary Cholangitis (PBC) typically ranges from 13–15 mg/kg/day and is often administered in divided doses (two to four times daily). Conversely, the usual dose for gallstone dissolution is lower, often around 8–12 mg/kg/day.


Administration and Scheduling

The total daily quantity is typically taken with food to support absorption. While treatment often begins with divided doses, some regimens for PBC allow the total dose to be consolidated to once daily (preferably in the evening) after the initial three months of therapy. Tablets with scores are available to facilitate precise, weight-based dosing adjustments. If a dose is missed, it should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped to avoid doubling the dose.


Treatment Duration

Use for chronic conditions such as PBC is generally classified as long-term therapy. In contrast, therapy for gallstone dissolution is a time-bound course, typically lasting six to 24 months, and must continue for three months after complete stone clearance is confirmed by imaging. Pediatric patients with certain liver conditions are given a higher, weight-adjusted dose starting at 20 mg/kg/day in divided doses.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Udex

Evidence for Use in Primary Biliary Cholangitis (PBC)

The research base for Udex in Primary Biliary Cholangitis (PBC) consists of an extensive collection of data, including foundational Randomized Controlled Trials (RCTs) and comprehensive, multi-year observational cohort studies. The research conducted was centered on adults diagnosed with PBC, covering individuals both before symptoms appeared and those with noticeable disease activity.

Researchers designed these studies to monitor major clinical events, such as endpoints related to liver transplantation and patient survival, and measurements of disease progression into more advanced stages. They also closely monitored biochemical markers in the blood, such as specific liver enzymes and bilirubin, as measures used to study patterns of change related to liver-specific biomarkers.

Evidence for Use in Cholesterol Gallstones

Research explored whether Udex could be used for the dissolution of specific types of gallstones through Randomized Controlled Trials (RCTs) and prospective clinical trials. This research focused on adults who had small or medium-sized gallstones that were predominantly composed of cholesterol, often referred to as radiolucent gallstones, and only when the gallbladder was still functioning.

The primary outcomes research examined were physical endpoints, specifically the gallstone dissolution rate. This rate reflects the percentage of patients where gallstone clearance was monitored or a measured reduction in stone volume was observed. A key limitation noted is that the results apply only to the populations studied with cholesterol-rich, non-calcified stones. The measured dissolution rates were observed to be lower for larger or more numerous stones.

Consistency, Limitations, and Unresolved Research Questions

Since PBC is a chronic condition, the research explored long-term outcomes through extended observation periods, often spanning many years in observational cohort studies. However, certainty remains low regarding the long-term disease course for every subgroup, and research is ongoing to fully establish the durability of observed outcomes.

One area where findings were mixed is the data collected for patient-reported outcomes, particularly pruritus (itching) and fatigue. Furthermore, evidence quality varies across studies, and while large trials provide insight into the general population, subgroup findings are uncertain for specific combinations of disease stage and other pre-existing conditions.

Key Studies & References

  1. Ursodeoxycholic Acid - MedlinePlus (Drug Classification and Properties)
  2. Ursodiol (Ursodeoxycholic Acid) - NIH MedlinePlus Drug Information (Uses for PBC and Gallstones)

Frequently Asked Questions (FAQ)

Common questions about Udex (FAQ)

Q: How quickly does Udex usually start working for people?

Studies and official information indicate that Udex works over time by changing the composition of bile. Because of this mechanism, the full therapeutic response is often assessed after a sustained period of treatment, typically ranging from 3 to 6 months of continuous use. For gallstone dissolution, follow-up imaging to check for stone clearance usually occurs at 6-month intervals.

Q: Is it normal to feel [vague side effect like dizziness/tiredness] when starting Udex?

Regulatory safety documents classify certain central nervous system (CNS) effects as reported adverse reactions. These effects, which include sleep disorder, headache, and fatigue, are generally described as uncommon or were reported through post-marketing surveillance. The appearance of these effects is grounds for discussion with a doctor.

Q: If I miss a dose of Udex, what should I generally do?

According to the official product information, official guidelines state that a missed dose may be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped entirely. The instructions clearly state that a double dose should not be taken to make up for the forgotten one.

Q: Can older people (seniors) use Udex?

Use in the elderly population is covered in the official documentation. Regulatory information establishes the medicine's use in older people and does not specify different maximum dosages or special precautions solely for geriatric patients compared to other adults.

Q: What kind of monitoring or tests are needed while taking Udex?

Official regulatory guidance states that liver function parameters must be monitored by a healthcare provider. These typically include blood tests like AST, ALT, and gamma-GT. This monitoring is generally recommended every 4 weeks during the first three months of treatment, and every 3 months thereafter.

Q: Can women who are pregnant or breastfeeding use Udex?

Udex is generally not recommended for use during pregnancy or breastfeeding. Additionally, for women who can become pregnant and are being treated for gallstone dissolution, official labeling advises the use of effective non-hormonal contraception. This is because hormonal contraceptives may counteract the drug's intended effect.

Q: Why does Udex need to be prescribed by a doctor?

Udex is classified as a Prescription-Only Medicine (POM) in major regulatory jurisdictions. This status is required because the drug is used to manage serious, chronic conditions and necessitates medical supervision and periodic monitoring of important health markers, like liver function, during the course of treatment.

Q: Do I need to change my diet while taking Udex?

Regulatory documents do not outline a specific required diet, but the medication is typically taken with food to support absorption. The official documentation describes that certain medications, such as Estrogens, Oral Contraceptives, and Fibrates, are noted to potentially counteract Udex's intended effect, which may restrict their co-administration for gallstone dissolution.

Q: What happens if someone takes too much Udex?

Official documentation for overdose indicates that the most common finding is diarrhea. Other severe symptoms are considered unlikely. Treatment for diarrhea resulting from an overdose focuses on managing symptoms, including restoring fluid and electrolyte balance.

Q: Does Udex cause problems with sleep?

Regulatory safety information lists sleep disorder or sleep disturbances among the potential side effects that have been reported by patients taking the medication.

Q: What does it mean if Udex has a 'Black Box Warning'?

Official documentation for Udex does not contain a Black Box Warning (formally known as a Boxed Warning by the FDA). This designation is a serious measure reserved for drugs where risks must be clearly highlighted, and its absence indicates that the most severe warnings are addressed elsewhere in the official regulatory documents.

Q: How long does the effect of a single dose of Udex typically last?

Research on the drug's elimination indicates that the half-life is approximately 2 to 3 hours after a single dose. However, the drug functions within the enterohepatic system (the circulation between the gut and liver), meaning its long-term effects on the overall bile acid pool are more sustained than the half-life of a single dose suggests.

Q: What if I start feeling better, can I stop taking Udex then?

Official instructions advise that treatment should be continued for as long as directed by a doctor. For gallstone dissolution, therapy must continue for approximately three months after stones appear dissolved based on imaging. Patients are advised not to stop taking the medicine without specific medical guidance.

Q: Is Udex absorbed better if taken at a certain time of day?

Official prescribing regimens generally recommend taking the medicine with food to support absorption. For Primary Biliary Cholangitis (PBC), some regimens allow the total daily dose to be taken once daily (preferably in the evening) after an initial treatment period.

Q: Is the information about Udex side effects based on long-term or short-term studies?

The official safety profile is compiled from data collected across both short-term Randomized Controlled Trials and extensive, multi-year observational cohort studies. This combination of evidence provides information on both immediate reactions and effects seen over longer periods, particularly for chronic uses like Primary Biliary Cholangitis (PBC).

Q: Why do doctors prescribe different dosages of Udex?

Dosing, as described in official prescribing information, is precisely determined by several factors. These factors include the specific condition being managed (e.g., PBC versus gallstone dissolution), the patient’s body weight, and sometimes the patient’s age (e.g., pediatric patients require different calculations).

Q: Is Udex considered an immunosuppressant?

Udex is officially classified as a Bile Acid Preparation and a Choleretic Agent, which describes its core function of modifying bile and promoting bile flow. While some research may suggest it has an immunomodulating (immune-influencing) effect, its primary regulatory classification is based on its established bile-modifying and cell-protecting properties.

Q: Do you need to take Udex for a minimum amount of time?

Yes, for the treatment of cholesterol gallstones, the therapy is explicitly time-bound in the official documentation. It must continue for a minimum of three months after complete stone clearance has been confirmed by medical imaging to help prevent recurrence.

Q: Can Udex be split or crushed to make it easier to swallow?

Official documentation notes that scored tablets are available primarily to facilitate precise, weight-based dosing adjustments. Any alteration to the tablet for ease of swallowing is grounds for discussion with a prescribing physician.

Q: How long after stopping Udex does it take for the drug to leave the body?

The half-life, which measures how quickly the drug is cleared from the systemic circulation, is approximately 2 to 3 hours. However, the drug is involved in the enterohepatic recirculation system, meaning its influence on the bile acid pool is maintained longer than the measured half-life of a single dose.

How should Udex be stored and disposed of?

How to Store and Dispose of Udex (Ursodeoxycholic Acid)

Storage Requirements

Official labeling requires Udex (ursodeoxycholic acid) to be stored at Controlled Room Temperature, generally defined as below 30 C (86 F). The medicine must be kept in its original container and the container should be tightly closed to provide necessary protection from moisture and light. To ensure safety, Udex must always be stored out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Udex must follow local regulatory requirements. Official documentation specifies that the medication should not be disposed of via wastewater or mixed with household trash unless explicitly instructed by the local drug take-back or disposal program. If a take-back option is unavailable, specific guidance, such as the FDA's procedure for mixing the drug with an undesirable substance, may be followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Udex found in:

A-Z Index: